Leeward Investments LLC MA Has $16.04 Million Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA increased its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 17.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 452,438 shares of the life sciences company’s stock after buying an additional 68,247 shares during the period. Leeward Investments LLC MA owned about 0.58% of Integra LifeSciences worth $16,039,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital Research Global Investors grew its stake in shares of Integra LifeSciences by 40.1% in the fourth quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock worth $187,149,000 after purchasing an additional 1,228,996 shares during the last quarter. Norges Bank bought a new position in shares of Integra LifeSciences during the fourth quarter worth about $29,272,000. Point72 Europe London LLP lifted its stake in shares of Integra LifeSciences by 54.9% in the fourth quarter. Point72 Europe London LLP now owns 719,663 shares of the life sciences company’s stock worth $31,341,000 after acquiring an additional 255,201 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Integra LifeSciences by 36.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 715,294 shares of the life sciences company’s stock valued at $31,151,000 after acquiring an additional 191,529 shares during the last quarter. Finally, Cooke & Bieler LP increased its position in Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after purchasing an additional 120,410 shares during the period. 84.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Citigroup increased their price objective on shares of Integra LifeSciences from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 22nd. Morgan Stanley dropped their price objective on Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 7th. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $45.00 to $25.00 in a research note on Tuesday, May 7th. Truist Financial cut their price target on Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating on the stock in a report on Tuesday, May 7th. Finally, Bank of America dropped their target price on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $33.88.

Integra LifeSciences Stock Down 1.6 %

IART traded down $0.46 during trading on Thursday, hitting $28.73. 833,632 shares of the company’s stock were exchanged, compared to its average volume of 2,191,991. The stock has a market cap of $2.26 billion, a P/E ratio of 57.46, a PEG ratio of 1.05 and a beta of 1.11. The business’s 50 day moving average is $28.60 and its two-hundred day moving average is $35.32. Integra LifeSciences Holdings Co. has a fifty-two week low of $22.36 and a fifty-two week high of $46.75. The company has a quick ratio of 3.35, a current ratio of 4.68 and a debt-to-equity ratio of 1.15.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. The business had revenue of $368.90 million for the quarter, compared to analysts’ expectations of $361.96 million. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 EPS. As a group, equities analysts expect that Integra LifeSciences Holdings Co. will post 3.03 earnings per share for the current fiscal year.

Insider Activity at Integra LifeSciences

In other news, Chairman Stuart Essig acquired 52,641 shares of Integra LifeSciences stock in a transaction on Thursday, May 23rd. The stock was acquired at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the transaction, the chairman now owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.